Delcath Systems, Inc. DCTH
We take great care to ensure that the data presented and summarized in this overview for DELCATH SYSTEMS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DCTH
View all-
Vivo Capital, LLC Palo Alto, CA1.71MShares$21 Million3.93% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.39MShares$17 Million6.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$15 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT801KShares$9.84 Million0.66% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY612KShares$7.52 Million0.08% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA419KShares$5.14 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny315KShares$3.86 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il290KShares$3.56 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA289KShares$3.55 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO259KShares$3.18 Million0.07% of portfolio
Latest Institutional Activity in DCTH
Top Purchases
Top Sells
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Insider Transactions at DCTH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Dec 24
2024
|
Steven A J Salamon Director |
BUY
Conversion of derivative security
|
Indirect |
250,000
+7.66%
|
$2,500,000
$10.0 P/Share
|
|
Dec 24
2024
|
Gil Aharon Director |
BUY
Conversion of derivative security
|
Indirect |
250,000
+7.66%
|
$2,500,000
$10.0 P/Share
|
|
Dec 24
2024
|
Rosalind Advisors, Inc. Director |
BUY
Conversion of derivative security
|
Indirect |
250,000
+7.66%
|
$2,500,000
$10.0 P/Share
|
|
Oct 22
2024
|
Gerard J Michel CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+4.96%
|
$99,996
$6.0 P/Share
|
|
Apr 18
2024
|
Gil Aharon Director |
BUY
Conversion of derivative security
|
Indirect |
991,615
+27.0%
|
-
|
|
Apr 18
2024
|
Gil Aharon Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
619,946
+18.78%
|
$3,843,045,254
$6199.46 P/Share
|
|
Apr 18
2024
|
Steven A J Salamon Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
619,946
+18.49%
|
$3,843,045,254
$6199.46 P/Share
|
|
Apr 18
2024
|
Steven A J Salamon Director |
BUY
Conversion of derivative security
|
Indirect |
991,615
+26.63%
|
-
|
|
Apr 18
2024
|
Rosalind Advisors, Inc. Director |
BUY
Conversion of derivative security
|
Indirect |
991,615
+26.41%
|
-
|
|
Apr 18
2024
|
Rosalind Advisors, Inc. Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
619,946
+18.32%
|
$3,843,045,254
$6199.46 P/Share
|
|
Mar 19
2024
|
Gil Aharon Director |
BUY
Open market or private purchase
|
Direct |
26,882
+2.45%
|
$80,646
$3.72 P/Share
|
|
Mar 19
2024
|
Steven A J Salamon Director |
BUY
Open market or private purchase
|
Direct |
26,882
+2.34%
|
$80,646
$3.72 P/Share
|
|
Mar 19
2024
|
Sandra Pennell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,881
+30.57%
|
$80,643
$3.72 P/Share
|
|
Mar 19
2024
|
Gerard J Michel CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,323
+11.76%
|
$120,969
$3.72 P/Share
|
|
Mar 19
2024
|
Vojo Vukovic CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,882
+17.48%
|
$80,646
$3.72 P/Share
|
|
Mar 19
2024
|
David L. Hoffman GEN'L COUNSEL, CCO & SECY |
BUY
Grant, award, or other acquisition
|
Direct |
20,161
+21.34%
|
$60,483
$3.72 P/Share
|
|
Mar 19
2024
|
Kevin Muir GM INTERVENTIONAL ONCOLOGY |
BUY
Grant, award, or other acquisition
|
Direct |
13,441
+41.97%
|
$40,323
$3.72 P/Share
|
|
Dec 12
2023
|
Vojo Vukovic CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
40,000
+28.57%
|
$120,000
$3.0 P/Share
|
|
Dec 08
2023
|
Gerard J Michel CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
34,000
+11.47%
|
$68,000
$2.94 P/Share
|
|
Nov 17
2023
|
Rosalind Advisors, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+8.78%
|
$200,000
$2.4 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 750K shares |
|---|---|
| Exercise of conversion of derivative security | 16.7K shares |